BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Polymedco Introduces Point of Care Test for Recurrent Bladder Cancer Detection


4/11/2007 12:04:03 PM

CORTLANDT MANOR, N.Y., April 11 /PRNewswire/ -- Polymedco, Inc. is pleased to announce the introduction of the BTA stat(R) test -- a point of care technology for the early detection of recurrent bladder cancer. This method uses monoclonal antibodies to detect the presence of bladder tumor associated antigen in urine. It is a single-step, rapid immunochromatographic assay for bladder tumor-associated antigen in voided urine. The specificity of the BTA stat(R) test was 93-95% in patients with non-genitourinary diseases and cancers and healthy individuals tested as part of a multi-center study. The test has a sensitivity that is considerably higher than voided urine cytology, enabling detection of recurrent early stage and grade cancers that cytology often misses. Requiring five drops of urine, the result is delivered in only five minutes. The appearance of a line in the patient window indicates a positive result. The BTA stat(R) test requires one voided urine sample with no sample preparation.

Bladder cancer is the fourth most common cancer among men and tenth among females. 57,400 people will be diagnosed with the disease in 2007. It has a 5-year survival rate of 94% if caught early and recurs in over 88% of patients within fifteen years, calling for regular testing and lifelong management.

Polymedco, Inc. is one of the leading marketing and distribution companies in the clinical laboratory marketplace. Since the company's inception in 1980, Polymedco has evolved into a highly skilled and successful marketing and sales and manufacturing organization.

For More Information, please contact Polymedco at 800-431-2123 or 914-739-5400, or visit our website: http://www.polymedco.com; http://www.btastat.com

Polymedco, Inc.

CONTACT: Helen Landicho of Polymedco, Inc., +1-216-262-7363,hlandicho@polymedco.com


Read at BioSpace.com


Polymedco
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->